| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 09/12/2002 | WO2002070459A1 Novel amino dicarboxylic acid derivatives |
| 09/12/2002 | WO2002070068A2 Lipoxin analogs as novel inhibitors of angiogenesis |
| 09/12/2002 | WO2002070011A2 Treatment of ppar mediated diseases |
| 09/12/2002 | WO2002070008A1 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 09/12/2002 | WO2002069980A2 Pharmaceutically effective ginsenosides and their use |
| 09/12/2002 | WO2002069977A1 Use of certain steroids for treatment of blood cell deficiencies |
| 09/12/2002 | WO2002069972A2 Triazole compounds and the use thereof in the prophylaxis and therapy of neurodegenerative diseases, cerebral trauma and cerebral ischemia |
| 09/12/2002 | WO2002069970A1 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| 09/12/2002 | WO2002069967A1 Percutaneous absorption compositions |
| 09/12/2002 | WO2002069965A1 Benzimidazole derivatives as therapeutic agents |
| 09/12/2002 | WO2002069948A1 Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders |
| 09/12/2002 | WO2002069946A2 Use of triazole compounds for prophylaxis and in therapy for neurodegenerative illnesses, brain traumas and cerebral ischaemia |
| 09/12/2002 | WO2002069930A1 Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| 09/12/2002 | WO2002069905A2 Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders |
| 09/12/2002 | WO2002069899A2 Methods and compositions for the treatment and prevention of smooth muscle cell proliferation |
| 09/12/2002 | WO2002069886A2 Modified proteins, designer toxins, and methods of making thereof |
| 09/12/2002 | WO2002044187A3 Cyclic salen-metal compounds as scavengers for oxygen radicals and useful as antioxidants in the treatment and prevention of diseases |
| 09/12/2002 | WO2002043742A8 Cyclodextrins and reversal of atherosclerosis |
| 09/12/2002 | WO2002028859A3 Condensed pyridoindole derivatives |
| 09/12/2002 | WO2002026717A3 Hydroxy acid integrin antagonists |
| 09/12/2002 | WO2002014369A3 Human kininogen d5 domain polypeptides and their use |
| 09/12/2002 | WO2001096334A3 Heteroarylalkanoic acids as integrin receptor antagonists |
| 09/12/2002 | WO2001089558A3 Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states |
| 09/12/2002 | WO2001089520A3 Dehydroascorbic acid formulations and uses thereof |
| 09/12/2002 | WO2001047562A3 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol) |
| 09/12/2002 | WO2001047509A3 Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions |
| 09/12/2002 | WO2001045641A3 Inhibitors of thrombin induced platelet aggregation |
| 09/12/2002 | WO2001030848A3 Nucleic acids of the human abc1 gene and applications thereof |
| 09/12/2002 | WO2001015694A9 Extended duration light activated cancer therapy |
| 09/12/2002 | WO2001012210A9 Methods and compositions useful for modulation of angiogenesis using tyrosine kinase raf and ras |
| 09/12/2002 | US20020129388 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of atherosclerosis |
| 09/12/2002 | US20020129385 Medthods for improving long-term memory storage and retrieval |
| 09/12/2002 | US20020128494 N-Disubstituted carbamoyloxy flavones |
| 09/12/2002 | US20020128481 Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists |
| 09/12/2002 | US20020128471 Useful for treating cellular hyperproliferation |
| 09/12/2002 | US20020128459 Physiologically active protein originating in mammals |
| 09/12/2002 | US20020128436 Therapeutic composition for use in the treatment of autoimune and rheumatic diseases |
| 09/12/2002 | US20020128316 Neuroprotective composition and uses thereof |
| 09/12/2002 | US20020128306 Programmed cell death; expansion of hematopoietic cells, for prolonging viability of an organ for transplantation, and maintaining viability of cell lines used in bioproduction |
| 09/12/2002 | US20020128297 Amlodipine hemimaleate |
| 09/12/2002 | US20020128296 Aspartate derivative of amlodipine |
| 09/12/2002 | US20020128287 Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents |
| 09/12/2002 | US20020128279 Potassium channel blocking agents |
| 09/12/2002 | US20020128278 Inhibit some of the ill effects caused by diabetes or by aging; preventing premature aging, rheumatoid arthritis, Alzheimer's disease, uremia, neurotoxicity, atherosclerosis and spoilage of proteins in food |
| 09/12/2002 | US20020128266 ABCA-1 elevating compounds |
| 09/12/2002 | US20020128265 CRF receptor antagonists and methods relating thereto |
| 09/12/2002 | US20020128263 Treatment or prevention of mGluR5 receptor mediated disorders. |
| 09/12/2002 | US20020128259 Using a vasopressin antagonist such as conivaptan |
| 09/12/2002 | US20020128255 Substituted hydroxyl amine derivatives; inhibitors of beta-secretase, inhibit beta-secretase-mediated cleavage, inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques |
| 09/12/2002 | US20020128253 Diphenylazetidinone derivatives, process for their preparation, medicaments comprising these compounds and their use |
| 09/12/2002 | US20020128252 Diphenylazetidinone derivatives, process for their preparation, medicaments comprising these compounds and their use |
| 09/12/2002 | US20020128247 Phenyl sulfamide derivatives as dietetics, antidiabetics, and hypotensive agents |
| 09/12/2002 | US20020128225 Methods and products related to pulmonary delivery of polysaccharides |
| 09/12/2002 | US20020128217 Therapeutic use of cis-element decoys in vivo |
| 09/12/2002 | US20020127694 2786, a novel human aminopeptidase |
| 09/12/2002 | US20020127676 Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| 09/12/2002 | US20020127668 Polypeptide for use in the diagnosis and treatment of cancer, nervous system and vessicular transport disorders |
| 09/12/2002 | US20020127605 Cyclophilin compound for use in the treatment of infections, nervous system, skin, ischemic and vision disorders |
| 09/12/2002 | US20020127248 Using rapamycin compound for therapy and prophylaxis of neointimal proliferation and thickening |
| 09/12/2002 | US20020127230 Transcutaneous photodynamic therapy ("PDT") of a target tissue |
| 09/12/2002 | US20020127227 Antagonist monoclonal antibodies (mAb) that bind to the RHAMM (receptor for hyaluronic acid mediated motility) receptor; useful for preventing proliferative disease states in a mammal |
| 09/12/2002 | US20020127221 Urocortin proteins and uses thereof |
| 09/12/2002 | US20020127210 Transplants for myocardial scars |
| 09/12/2002 | US20020127198 Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| 09/12/2002 | DE10111877A1 Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate New imidazolidine derivatives, their preparation, their use and pharmaceutical compositions containing them |
| 09/12/2002 | DE10110750A1 Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften Novel Aminodicarbonsäurederivate with pharmaceutical properties |
| 09/12/2002 | DE10110749A1 Substituierte Aminodicarbonsäurederivate Substituted Aminodicarbonsäurederivate |
| 09/12/2002 | DE10110747A1 Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung Substituted 2,6-diamino-3,5-dicyano-4-aryl-pyridines and their use |
| 09/12/2002 | DE10107261A1 Pharmazeutische Zusammensetzung Pharmaceutical composition |
| 09/12/2002 | CA2440803A1 Modulators of chemokine receptor activity |
| 09/12/2002 | CA2440642A1 Dimeric isoflavones |
| 09/12/2002 | CA2440038A1 Substituted 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines and use thereof |
| 09/12/2002 | CA2439945A1 Novel halogen-substituted aminodicarboxylic acid derivatives |
| 09/12/2002 | CA2439941A1 Secreted proteins |
| 09/12/2002 | CA2439939A1 Novel aminodicarboxylic acid derivatives |
| 09/12/2002 | CA2439934A1 Use of protein histidine phosphatase |
| 09/12/2002 | CA2439933A1 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 09/12/2002 | CA2439854A1 Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylatoin status of the genes |
| 09/12/2002 | CA2439849A1 Antagonists of mcp-1 function and methods of use thereof |
| 09/12/2002 | CA2439779A1 Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the dna |
| 09/12/2002 | CA2439759A1 Substituted amino dicarboxylic acid derivatives |
| 09/12/2002 | CA2439691A1 Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders |
| 09/12/2002 | CA2439687A1 Use of certain steroids for treatment of blood cell deficiencies |
| 09/12/2002 | CA2439647A1 Side-chain-halogenated aminodicarboxylic acid derivatives as medicaments for treatment of cardiovascular disorders |
| 09/12/2002 | CA2439644A1 Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours |
| 09/12/2002 | CA2439594A1 Interleukin-8 homologous polypeptides and therapeutic uses thereof |
| 09/12/2002 | CA2439581A1 Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders |
| 09/12/2002 | CA2439205A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439203A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439200A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439197A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439196A1 Nuclear hormone receptor ligand binding domains |
| 09/12/2002 | CA2439195A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439192A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2438737A1 Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as ip antagonists |
| 09/12/2002 | CA2438326A1 Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| 09/12/2002 | CA2437594A1 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 09/12/2002 | CA2435277A1 Chimeric polypeptides of serum albumin and uses related thereto |
| 09/12/2002 | CA2434066A1 Chromane derivatives, process for their preparation and their use as antitumor agents |
| 09/12/2002 | CA2432280A1 Novel glutamate receptor modulatory proteins and nucleic acid molecules and uses therefor |